Elsevier

Experimental Neurology

Volume 141, Issue 2, October 1996, Pages 225-239
Experimental Neurology

Regular Article
Pharmacokinetics of Intrathecally Applied BDNF and Effects on Spinal Motoneurons

https://doi.org/10.1006/exnr.1996.0157Get rights and content

Abstract

Brain-derived neurotrophic factor (BDNF) is a potential drug for treatment of amyotrophic lateral sclerosis. Previous studies have demonstrated little or no penetration of the blood–brain barrier by BDNF, hence systemic application does not result in significant penetration into the spinal cord to produce direct action on motoneurons. Intrathecal (i.th.) application of BDNF to sheep was investigated as a mean of topical administration. After continuous infusion a caudal-cranial gradient of BDNF concentration in cerebrospinal fluid (CSF) and at the meninges was observed. BDNF did not penetrate spinal parenchyma but accumulated in spinal motoneurons probably due to axonal uptake in ventral roots and subsequent retrograde transport. Spinal motoneurons showed reduced levels of tropomyosin receptor kinase (trk) B and increased levels of c-fos at high BDNF doses in comparison to treatment with saline, even after treatment periods of several months. After bolus injection and cessation of continuous delivery multiphasic reduction of the BDNF concentration in CSF was detected. Our study demonstrates that i.th. application of BDNF is feasible, setting the stage for future clinical trials.

References (0)

Cited by (80)

  • BDNF-mediated preservation of spiral ganglion cell peripheral processes and axons in comparison to that of their cell bodies

    2021, Hearing Research
    Citation Excerpt :

    Over a course of 8 weeks, the amount of BDNF that could diffuse into the cochlea was calculated to be in the order of 1 ng. In addition, BDNF has a short half-life varying from less than a minute up to 3 h (Poduslo and Gurran, 1996; Dittrich et al., 1996; Sakane and Partridge, 1997; Kishino et al., 2001). Starting with 20 µg BDNF in 200 µl and a flow rate of 0.25 µl/h, ~17 µg BDNF would have been infused into the cochlea after 28 days.

  • A subpopulation of Bdnf-e1–expressing glutamatergic neurons in the lateral hypothalamus critical for thermogenesis control

    2020, Molecular Metabolism
    Citation Excerpt :

    Thus, a single injection of the antibody into LH resulted in an increase in Ucp1 expression for as long as 2 weeks (Figure 7F). In contrast, the t1/2 of BDNF is only a few hours [66], and therefore, BDNF needs to be delivered constantly through a cannula implantation of an osmotic pump. Viral expression of BDNF could avoid the short t1/2 problem, but it may elicit some unwanted side effects caused by overexpression and/or activation of its low-affinity receptor p75NTR in addition to TrkB.

  • Therapeutic potential of a TrkB agonistic antibody for ischemic brain injury

    2019, Neurobiology of Disease
    Citation Excerpt :

    Moreover, a number of studies have reported that intravenous administration of BDNF prior to stroke onset reduced infarct volume and improved functional recovery in animal models of stroke, partially through apoptosis suppression (Schabitz et al., 2000; Zhang and Pardridge, 2001a,b; Schäbitz et al., 2004; Zhang and Pardridge, 2006; Schäbitz et al., 2007; Lu et al., 2016). Despite all the positive modulatory and repair activities of BDNF, its short half-life, minimal tissue penetration (Dittrich et al., 1996), and non-specific activation of p75 neurotrophin receptor (p75NTR) (Kraemer et al., 2014) hinder the development of BDNF as a therapeutic agent against ischemic stroke. Neuronal cell death could be mediated by multiple mechanisms.

View all citing articles on Scopus
View full text